Dr. Andrew Zelenetz, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Lymphoma
Studies T-Lymphoblastic Leukemia/Lymphoma
4 reported clinical trials
6 drugs studied
Area of expertise
1Lymphoma
ALK positive
TP53 positive
2T-Lymphoblastic Leukemia/Lymphoma
TP53 positive
Affiliated Hospitals
Clinical Trials Andrew Zelenetz, MD is currently running
Triple Combo Therapy
for Chronic Lymphocytic Leukemia
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Recruiting1 award Phase 216 criteria
SBRT
for Prostate Cancer
The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for people with unfavorable intermediate-risk prostate. The researchers will see whether SBRT can prevent participants' cancer from coming back and/or spreading to other parts of the body. In addition, they will look closely at how safe and effective it is to rely on Decipher test results for determining which patients would benefit from more extensive radiation treatments
Recruiting1 award Phase 2
More about Andrew Zelenetz, MD
Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Andrew Zelenetz, MD has experience with
- Venetoclax
- Obinutuzumab
- Zanubrutinib
- Rituximab
- Belantamab Mafodotin
- Stereotactic Body Radiation Therapy (SBRT)
Breakdown of trials Andrew Zelenetz, MD has run
Lymphoma
T-Lymphoblastic Leukemia/Lymphoma
Lymphoid Leukemia
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Zelenetz, MD specialize in?
Andrew Zelenetz, MD focuses on Lymphoma and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Lymphoma has involved ALK positive patients, or patients who are TP53 positive.
Is Andrew Zelenetz, MD currently recruiting for clinical trials?
Yes, Andrew Zelenetz, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Andrew Zelenetz, MD has studied deeply?
Yes, Andrew Zelenetz, MD has studied treatments such as Venetoclax, Obinutuzumab, Zanubrutinib.
What is the best way to schedule an appointment with Andrew Zelenetz, MD?
Apply for one of the trials that Andrew Zelenetz, MD is conducting.
What is the office address of Andrew Zelenetz, MD?
The office of Andrew Zelenetz, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.